Stomach Cancer

Shaping your forecasting.

Welcome to theHub

Stomach Cancer

Stomach cancer is a broad term encompassing tumours arising in the stomach.

Read More about Stomach Cancer

Includes gastric carcinoma which is a malignant epithelial-origin tumour commonly developing after prolonged period of gastritis. Stomach cancers tend to develop slowly over many years spreading in different ways. Staging for stomach cancer is as per AJCC stage at diagnosis and Lauren classification for Adenocarcinoma. Main symptoms and co-morbidities for the disease include:

History of stomach polyps or stomach lymphoma
Family history of stomach cancer
Family history of hereditary non-polyposis
Colorectal cancer
Familial adenomatous polyposis
BRCA1 or BRCA2 mutations
Megaloblastic (pernicious) anaemia or being blood type A.

Epidemiology Data

Data Available: Incidence Data

Data covers: Males and Females (where applicable) from 2010 to 2050.

Data is split into 5 year age ranges (0-4, 5-9 etc) from 0 to 100+ years, across multiple countries.

Additional sub filters of the data are available. Please see the below pop up box for more information.

Once purchased, the data will be provided in an embedded PowerBI document, in which the data can be filtered and viewed in a way which suits your needs. Raw data can also be downloaded. Below is an example embedded data set which can be filtered in a similar way.

Instructions:
Once the data set has been purchased, please refresh this page. The example data set will then be replaced with actual data.

Please contact us for further information regarding filtering of the data, viewing the data, data available, custom quotes, or anything else.

Read More about the Data Filters available within the Epi Data

As well as incidence, data can be filtered by the following attributes :
• 1L metastatic treatment eligible
• 1L /2L/3L Treated
• AJCC stage
• BRCA1 mutation
• Cachexia
• H. Pylori infection
• HER2+
• Histopathology Adenoacanthoma
• Histopathology Adenocarcinoma
• Histopathology
• Location
• Lymph & metastases
• Neo and adjuvant treatment eligible
• PD-L1 expression
• Surgical intervention Gastrectomy
• Surgical intervention

Further sub sets are available within the data, please contact us for more information.

Countries Covered

Argentina
Australia
Austria
Belgium
Brazil
Canada
China
Denmark
Finland
France
Germany
India
Ireland
Italy
Japan
Mexico
Netherlands
Norway
Poland
Republic of Korea
Russian Federation
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Kingdom
United States of America

The more you buy, the more you save*

View cart

*discount added at checkout

For all your pharmaceutical
forecasting needs.

theHub is a portal of resources to help you create better forecasting. Courses, templates, software, data and working model examples to get you on the path to better forecasting. Sign up now to get access to a world of interactive content.

About J+D Forecasting.

At J+D it's our mission to simplify the complex nature of pharmaceutical forecasting to help support informed decision making for the future. We are dedicated to helping pharmaceutical and biotech companies use intelligent forecasting solutions to make strategic and operational investment decisions.

For decades, we have crafted bespoke pharmaceutical forecasting models, innovative software and interactive training solutions, each of which has been designed with client needs in mind, allowing businesses to create more intelligent and consistent insights.